In vivo (Athens, Greece) · 2020
Comparison of Three Fractionation Schedules in Radiotherapy for Early Glottic Squamous Cell Carcinoma.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Suzuki Gen, Yamazaki Hideya, Aibe Norihiro, Masui Koji, Shimizu Daisuke, Kimoto Takuya, Nishimura Takeshi, Kawabata Kanako, Nagasawa Shinsuke, Machida Kazutaka, Yoshino Yuki, Watanabe Sho, Sugiyama Yoichiro, Arai Akihito, Hirano Shigeru, Yamada Kei
Аннотация
BACKGROUND/AIM: Radiotherapy is widely accepted as the treatment of choice for early glottic squamous cell carcinoma (EGSCC), although it varies greatly with respect to dose, dose per fraction, and treatment techniques. The study aim was to evaluate the use of accelerated fractionation strategy (AFS) for EGSCC in standard clinical practice.
PATIENTS AND METHODS: Patients treated with definitive radiotherapy for EGSCC between 2008 and 2019 were retrospectively identified and received either conventional fractionation, hypofractionation, or hyperfractionation.
RESULTS: One hundred six patients were analyzed, and 19, 71, and 16 patients underwent conventional fractionation, hypofractionation, and hyperfractionation, respectively. The median follow-up was 56 months. The 5-year local control and overall survival rates were 79% and 83%; 78% and 79%; and 87% and 77%, respectively, and no significant difference was observed between the fractionation schedules.
CONCLUSION: Our findings confirmed the utility of AFS in standard clinical practice and support its use for patients with EGSCC.
PATIENTS AND METHODS: Patients treated with definitive radiotherapy for EGSCC between 2008 and 2019 were retrospectively identified and received either conventional fractionation, hypofractionation, or hyperfractionation.
RESULTS: One hundred six patients were analyzed, and 19, 71, and 16 patients underwent conventional fractionation, hypofractionation, and hyperfractionation, respectively. The median follow-up was 56 months. The 5-year local control and overall survival rates were 79% and 83%; 78% and 79%; and 87% and 77%, respectively, and no significant difference was observed between the fractionation schedules.
CONCLUSION: Our findings confirmed the utility of AFS in standard clinical practice and support its use for patients with EGSCC.